Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CSL Limited
While anticipated, the removal of the hold on uniQure’s hemophilia B program removes significant overhang, as the focus shifts to an anticipated FTC antitrust clearance of its CSL Behring deal.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
Accelerated Approval, Real World Evidence Pilot From ICER, Aetion Picks HAE As First Therapeutic Area
ICER signals how it will pick other therapies for pilot in interview with Pink Sheet. Aetion believes project will help 'pressure test' the RWE field and show health plans and providers the value of using real world evidence to supplement clinical trial data.
The impact of the coronavirus pandemic on the size of the pharma R&D pipeline in 2020 could be felt in a number of ways.
- Diagnostic Equipment & Supplies
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Other Names / Subsidiaries
- CSL Behring
- CSL Behring Mexico
- CSL Biotherapies
- CSL Bioplasma
- Wuhan Zhong Yuan Rui De Biological Products
- Calimmune, Inc.
- Vitaeris Inc.
- Zenyth Therapeutics Ltd.
- CSL, Ltd.